Keywords: Amgen, ImmunoGen, Anticancer therapeutics, Licensing, Shire, Arrowhead Research, Orphan diseases

Licensing deals for Amgen/ImmunoGen and Shire/Arrowhead

Article | 20 December 2012

US biotechnology company ImmunoGen (Nasdaq), which develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Shire

Amgen

ImmunoGen

Arrowhead Research

Go to company listing